As a result of recently completed initial testing in vitro on loaded Nuvec® with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec® works to deliver multiple siRNA into the same cell. With siRNA increasingly being used in the development [...]
Ultrasound sonication is a well-established mechanism for the deagglomeration of particle materials in dispersion. In this recently published paper, the National Physical Laboratory investigates the deagglomeration of Nuvec® silica particles with and without the presence of plasmid via controlled sonication. It evaluated the performance of controlled cavitation using different [...]
In collaboration with Nanomerics Ltd, N4 Pharma has released the results of a recent study assessing the potential of Nuvec® , a non-viral nanoparticle delivery system consisting of poly(ethylenimine) coated silica particles, as a gene therapy delivery platform in cancer treatment. Introducing exogenous genetic material to a cell alters [...]
N4 Pharma highlights the potential of Nuvec® as a gene therapy delivery platform by successfully completing a pre-clinical, in-vivo oncology study. The results reinforce the findings from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous (“i.v”) route of administration using [...]
N4 Pharma has successfully completed an in vivo confirmatory oncology study which reinforces the results from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous ("i.v") route of administration using a DNA plasmid (pDNA) encoding TNF alpha, to assess the [...]
"The development of smart drug delivery systems will improve drug efficacy, reduce costs, and improve storage, and ultimately lead to better treatments for the patient.” N4 Pharma’s CEO, Nigel Theobald, is featured in this month’s BioPharm International magazine talking about some of the next generation technologies that could be [...]
Our partners at Medicines Discovery Catapult gave a presentation on behalf of N4 Pharma at the European Laboratory Research & Innovation Group’s (ELRIG) UK meeting in Liverpool this week. The full poster, titled ‘Investigation of Nuvec® particles for effective gene delivery’, can be viewed by clicking here. We're also [...]
Our CEO, Nigel Theobald, is featured in the June issue of The Medicine Maker reviewing the progress made with #covid19vaccines so far. He also looks at how silica nanoparticles like Nuvec® can help to overcome some of the delivery issues that we’ve seen in the vaccines developed to date. "Now that [...]
With the release of the Company Report for 2020, N4 Pharma’s CEO, Nigel Theobald, has spoken to Directors Talk about the highlights of last year year. He provides an update on our new refined strategy to focus on three work streams and explains what the Patent in relation to [...]
N4 Pharma's CEO, Nigel Theobald, has been interviewed by IG UK on the company's growth so far and some of the research we are currently working on. Watch the interview in full below.
